telugu -responsible oversight strategies for genetic...
TRANSCRIPT
Responsible Oversight Strategies for Genome Editing
Technology in Agricultural Animals in the United States
Bhanu Telugu DVM.PHDSusan Harper, DVM (USDA-ARS)
Diane Wray-Cahen PHD (USDA-FAS)
Overview
• Introduction and Rationale for performing genome editing
• Discuss current Regulatory landscape
• Provide a case study
Animal Biotechnologies in Context
Change Genetic Makeup
Genetic Modification
▪Mass selection▪ Pedigree selection▪Marker‐assisted selection
▪ Transgenics (1980s)(GE Animals)
▪ Genome‐wide selection▪ Gene Editing (2000s) “Precision Breeding”
SCIENTIFIC
CONTINUUM
Objective
HaplotypesA B
HaplotypesA B
: Desired allele; :Undesired allele: Desired QTN; :Undesired QTN
Genetic bottleneck associated with conventional breeding
Deletion(NHEJ)
Replacement(HDR)
T
G
: Desirable allele; :Undesirable allele: Desirable QTN; :Undesirable QTN
Rational Selection via Genome editingto accelerate genetic selection
Rationale for Genome editing over Conventional Breeding
Genome editing:1. Gene deletion (knockout)2. Gene modification3. insertion (knockin)
Rationale:– Overcome otherwise low heritability
– Separate “linked” genes
– Increase precision and efficiency of introducing desirable traits (conventional breeding is random)
– Introduction of traits not available via conventional breeding
Genome Editing
Potential Benefits• Facilitates precise modifications• Faster, more reliable, and cheaper than
conventional breeding (long generation interval) to modify base pairs of genes
Potential Risks• Off-target edits• Reducing genetic diversity in genome edited
herds• Potential spread of edited genetic material into
non-target or closely related populations (bio-containment)- issue with some than others
Additional Legal and Ethical Concerns
• Perceived novel environmental risks (Potential benefit‐Enviropigs; Potential risks?)
• Misuse of technology for entertainment purposes and potentially nefarious reasons (Eg.,micropigs as pets in China; HOW IS DIFFERENT FROM DESIGNER DOG BREEDING)
• Application of technology developed in animals to human germline editing (NOTE: not somatic editing)
Mid‐1980’s expression of need for establishment of regulatory oversight in light of the transgenic animals that have been generated
How to Regulate Genome Edited Animals ?
Regulation Under the Coordinated Framework
FDA
USDA
EPA
Safe for the animal, agriculture
and the environment
Safe for usein food and feed
Safe for environment
Regulation of Biotechnology in the United States
Coordinated Framework – General Principles
Federal Role in the Safe Use of Biotechnology
• USDA does not regulate GE animals for Food production. It is the role of FDA [FDA has emerged as a de facto enforcer].
• The risks of genetically engineered (GE) organisms are not fundamentally different from the risks posed by non-GE organisms with similar traits.
• The existing laws provide adequate authority.
• Regulation should be science-based and conducted on a case-by-case basis (Need to be revisited for Editing animals).
• In 2009, the Food and Drug Administration (FDA) issued Guidance: Regulation of Genetically Engineered Animals Containing Heritable Recombinant DNA Constructs
• The FDA regulates the recombinant DNA construct as a “new animal drug”, “an article intended to alter the structure or function” of the animal (trigger)
• New animal drug approval is based on a showing that the product is “safe” (for animals, humans, and the environment) and “effective” for the intended use
Transgenic animals that have recombinant DNA (trigger) have clear guidelines
APHIS
FDA FDA
Commercialization of Animal Biotechnology
Transgenic models (mice, rats, zebrafish)
GloFish (2003) [Enforcement Discretion]
Oxitec mosquito (2014, Brazil)
Project on hold
X
Atryn Goat (2009, USA)
Finally approvedCommercialization ?
Enviropig (Canada) AquAdvantage Salmon (USA)
How to regulate edited animals that do not have recombinant DNA (trigger), or that are similar to
naturally occurring sequences?
Existing Regulatory Frameworks
• Many provisions intended for the regulation of conventional transgenic animals do not necessarily directly apply to animals produced through genome editing technologies.
• Regulations are already in place to protect the welfare and safety of animals, workers, the environment, and the public.
• Local oversight of genetic research involving animals includes:
• Institutional Animal Care and Use Committee (IACUC)• Institutional Biosafety Committee (IBC)
Institutional Animal Care and Use Committee (IACUC)
• Required by:• Animal Welfare Act Regulations (AWAR) when regulated species are used for research, testing, or teaching
• PHS Policy when PHS funding is received• NRC Guide for the Care and Use of Laboratory Animals and FASS Ag Guide
• Establishes local oversight of the welfare and safety of animals used for research, teaching, and/or testing
• Incorporates a harm‐benefit analysis to ensure the use of animals is justified
• USDA‐APHIS Animal Care Policy No. 10 requires facilities that produce cloned animals for regulated purposes to be licensed, and those that produce novel genetically engineered animals to be registered as research facilities.
• AWAR exempts agricultural animals used in food and fiber research and federal research programs.
Institutional Biosafety Committee (IBC)
• NIH Guidelines requirement for institutions that receive NIH funding
• Establishes local oversight for research involving recombinant or synthetic nucleic acid molecules
• NIH Guidelines requirements for transgenic animals include:
• Identification and disposal guidance for animals larger than traditional laboratory animals (e.g., cattle, swine, sheep, goats, horses, and poultry)
• Permanent marking of genetically engineered offspring within 72 hours of birth, if their size permits
• Distinct and biochemically assayable DNA sequences that permit transgenics to be identified from non‐transgenic animals
• Containment and confinement practices
Miscellaneous Regulations
• Clean Water Act (33 USC 1251) with respect to contaminated runoff from animal production facilities
• Occupational Safety and Health Administration (OSHA) workplace requirements
• CDC‐NIH “Biosafety in Microbiological and Biomedical Laboratories” (BMBL) laboratory safety requirements
• State and Local Regulations related to environmental protection and worker safety
• Relevant International Standards
Regulatory framework adapted at ARS, USDA for an editing project
• Goal is to produce pigs that do not serve as a reservoir for influenza.
• Foundation pigs will be used to produce offspring.
• Influenza challenge studies will be performed in offspring, requiring ABSL‐3 containment.
• Animals will be monitored for adverse genotypic and phenotypic stability, as well as unintended or adverse characteristics.
• Project has been reviewed by IACUC and IBC at the University and two ARS locations.
• Review process emphasized potential animal welfare implications, biosecurity concerns, laboratory safety, potential occupational health issues, and containment/confinement practices.
• Agreements were established to clarify specific institutional responsibilities, animal ownership, and oversight roles.
• No gaps perceived in current local and government oversight processes.
Regulatory framework adapted at ARS, USDA for an editing project
For More Information
USDA-APHIS-BRS:http://www.aphis.usda.gov/biotechnology/index.shtml
“Unified” website for U.S. Regulatory Agencies under the Coordinated Framework:
http://usbiotechreg.epa.gov/usbiotechreg/
EPA:http://www.epa.gov/pesticides/biopesticides/pips/index.htm
FDA-CFSAN:http://www.fda.gov/Food/Biotechnology/default.htm